We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


NeoStem Brings Technology for Long-Term Storage of Adult Stem Cells

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "NeoStem Brings Technology for Long-Term Storage of Adult Stem Cells"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

NeoStem, Inc. has announced the latest article in a growing body of press coverage on the trend toward long-term banking of adult stem cells appeared recently in the San Diego Business Journal.

Under NeoStem’s strategic business plan, the Company will provide stem cell collection and storage services through agreements with existing medical facilities around the country. The article spotlights one of the first of those facilities, the California Healthspan Institute, an anti-aging medical institute based in Encinitas, CA.

In addition to being one of the first NeoStem facilities, it is one of the first to provide adult stem cell extraction and long-term banking services.

Through the facility, health-conscious consumers; particularly those with a family history of serious illness such as cancer and heart disease; can pay a fee to have their own adult stem cells extracted and stored at the facility.

Scientists worldwide are working to develop new cures and therapies based on stem cell technology, with many focused on the use of so-called “autologous” stem cell therapies – or the use of a person’s own cells for their personal treatment.

“The use of autologous adult stem cells is thought to provide important advantages in both effectiveness and safety of any stem cell-based treatments ultimately developed and delivered to a patient,” said Dr. Robin Smith, NeoStem’s Chief Executive Officer.

“Planning ahead and storing the cells while still healthy is a form of “bio-insurance” that is gaining in popularity in the United States,” he continued.

The article can be viewed at http://www.trilogy-capital.com/tcp/neostem/sdbj.html.